First-ever Phase 3 study in HPV16-positive head and neck cancer demonstrates strong enrollment progress
PDS Biotech reported Q2 results alongside significant progress in its groundbreaking VERSATILE-003 Phase 3 trial evaluating PDS0101 (Versamune® HPV) combined with pembrolizumab for HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
The trial is now open to patient enrollment with the first trial site initiated and activation of additional clinical sites continuing, representing a major milestone for both the company and patients with this challenging cancer type.
Clinical Significance: This marks the first-ever Phase 3 study combining Versamune HPV with pembrolizumab, targeting 350 patients with FDA Fast Track designation promising an accelerated development path. The trial addresses a significant unmet need in HPV16-positive HNSCC, which represents approximately 25% of all head and neck cancers.
PDS Biotech’s Versamune platform uses a novel T-cell activation approach designed to generate robust immune responses against HPV16-associated cancers. The combination with Merck’s pembrolizumab (Keytruda) creates a dual mechanism targeting both tumor-specific antigens and checkpoint inhibition.
Recent Data Presentations: The company presented updated positive data from the VERSATILE-002 trial and additional studies at the 2025 ASCO Annual Meeting, providing further validation of the Versamune approach in head and neck cancers.
The VERSATILE-003 trial design received FDA clearance following protocol amendments submitted in November 2024, demonstrating regulatory alignment on the development path for this first-in-class immunotherapy combination.
